You are here: Home / Archives for January 2012
January 31, 2012
CVC In Talks To Buy Ahlsell

NEW YORK, January 31 (FinanceEnquiry.com) - The buyout firm that owns Formula One, CVC Capital Partners, has entered into an exclusive discussion to acquire a Swedish construction products supplier, Ahlsell.

The potential buyer has been given four weeks by Ahlsell’s current owners, Goldman Sachs Group Inc. (NYSE: GS) and Cinven Ltd., to finish the financing of its bid. The transac

Read more.

January 31, 2012
S and P Capital IQ Reiterates BUY Rating on Pfizer (PFE)

New York, January 31 (FinanceEnquiry.com) - Analyst Herman Saftlas of S&P Capital IQ reiterates his BUY rating on the shares of Pfizer (NYSE: PFE). The 12-month target price is set to $24.

In a research note published this morning, the analyst mentions that the company has reported its Q4 EPS results marginally ahead of the estimates, driven by tight cost controls and higher other i

Read more.

January 31, 2012
S and P Capital IQ Reiterates BUY Rating on Oshkosh Corp (OSK)

New York, January 31 (FinanceEnquiry.com) - Analyst Richard Tortoriello of S&P Capital IQ reiterates his BUY rating on the shares of Oshkosh Corporation (NYSE: OSK). The 12-month target price is set to $32.

In a research note published this morning, the analyst mentions that the company has reported its Dec Q EPS results substantially ahead of the estimate and the consensus. The ana

Read more.

January 31, 2012
Deutsche Bank Provides European Equity Research

LONDON, January 31 (FinanceEnquiry.com) - Deutsche Bank provides European equity research while upgrading its 2012 outlook.

In a research note published yesterday, the equity research analysts said that they previously mentioned that the upside in US growth and a balance in Asia would aid the equity markets, despite harsh downside possibilities in Euro area. As of now,

Read more.

January 31, 2012
Katz Group To Offload Independent, Franchise Units to McKesson (MCK)

NEW YORK, January 31 (FinanceEnquiry.com) - Katz Group Canada Inc. has entered into an agreement to sell its banner pharmacy division, Drug Trading Company, and its franchise pharmacy business, Medicine Shoppe Canada Inc., to McKesson Corp (NYSE: MCK). The seller expects to close the deal at a purchase price of nearly $920 million in cash.

As a part of the contract, McKesson is signing

Read more.

January 31, 2012
S and P Capital IQ Reiterates STRONG BUY Rating on Harris Corp (HRS), Target Price Raised

New York, January 31 (FinanceEnquiry.com) - Analyst Todd Rosenbluth of S&P Capital IQ reiterates his STRONG BUY rating on the shares of Harris Corporation (NYSE: HRS). The 12-month target price has been raised from $47 to $48.

In a research note published this morning, the analyst mentions that the company has reported its Q2 EPS results short of the estimate, with in line revenues

Read more.

January 31, 2012
Mercer (MERC) Hires Senior M and A Consultant

NEW YORK, January 31 (FinanceEnquiry.com) - A global leader in human resource consulting and related services Mercer (NASDAQ: MERC) has appointed Emily Boynton has as senior consultant for its M&A Consulting Services business. She will be based in the New York office of the company.

As a part of her role, Boynton will head key M&A consulting customer projects and business develo

Read more.

January 31, 2012
S and P Rating Services Assigns Ratings to Series 2012-1 Class A and Class B Notes of Ibis Re II Ltd

 NEW YORK, January 31 (FinanceEnquiry.com) - Standard & Poor’s Rating Services assigned issue credit ratings of ‘BB-(sf)’ and ‘B-(sf)’ to the Series 2012-1 Class A and Class B notes, respectively that are issued by Ibis Re II Ltd and exposed to losses from US hurricanes in the covered area.

In a research note published yesterday,

Read more.

January 31, 2012
S and P Capital IQ Reiterates BUY Rating on National Oilwell Varco (NOV)

New York, January 31 (FinanceEnquiry.com) - Analyst Stewart Glickman of S&P Capital IQ reiterates his BUY rating on the shares of National Oilwell Varco (NYSE: NOV). The 12-month target price is set to $99.

In a research note published this morning, Glickman mentions that before the release of Q4 results on Thursday, the commentary on takeup of FPSO orders is awaited, since those ha

Read more.

January 31, 2012
S and P Capital IQ Reiterates HOLD Rating on Lilly (LLY)

New York, January 31 (FinanceEnquiry.com) - Analyst Herman Saftlas of S&P Capital IQ reiterates his HOLD rating on the shares of Lilly (NYSE: LLY). The 12-month target price is set to $40.

In a research note published this morning, the analyst mentions that the company has reported its Q4 non-GAAP EPS results substantially ahead of the estimates. The robust sales of newer drugs, sol

Read more.